title: Endurance training changes in lipolytic responsiveness of obese adipose tissue.
abstract: The aim of this study was to investigate the effect of aerobic exercise training on the lipolytic response of adipose tissue in obese subjects. Thirteen men (body mass index = 36.9 +/- 1.3 kg/m2) were submitted to aerobic physical training on a cycloergometer (30-45 min, 4 days a wk) for 3 mo. Adipocyte sensitivity to the action of catecholamines and insulin was studied in vitro before and after training. Training induced a decrease in the percentage of fat mass (P < 0.05) without changing the body weight. Basal lipolysis and hormone-sensitive lipase activity were significantly decreased after training (P < 0.05). The lipolytic effects of epinephrine, isoprenaline (beta-adrenoceptor agonist), and dobutamine (beta1-adrenoceptor agonist) were significantly increased (P < 0.05) but not those of procaterol (beta2-adrenoceptor agonist). The antilipolytic effects of alpha2-adrenoceptor and insulin were significantly decreased (P < 0.05). Lipolysis stimulation by agents acting at the postreceptor level was unchanged after training. In conclusion, aerobic physical training in obese male subjects modifies adipose tissue lipolysis through an enhancement of beta-adrenergic response and a concomitant blunting of adipocyte antilipolytic activity.
authors.affiliation: Laboratoire des Adaptations de l'Organisme à l'Exercice Musculaire, Hôpital Purpan, 31059 Toulouse Cedex, France.
authors.forename: I
authors.initials: I
authors.lastname: De Glisezinski
authors.forename: F
authors.initials: F
authors.lastname: Crampes
authors.forename: I
authors.initials: I
authors.lastname: Harant
authors.forename: M
authors.initials: M
authors.lastname: Berlan
authors.forename: J
authors.initials: J
authors.lastname: Hejnova
authors.forename: D
authors.initials: D
authors.lastname: Langin
authors.forename: D
authors.initials: D
authors.lastname: Rivière
authors.forename: V
authors.initials: V
authors.lastname: Stich
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D008055:Lipids / Q000097:blood; D008066:Lipolysis / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism*; D010806:Physical Education and Training; D010807:Physical Endurance / Q000502:physiology*; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D011943:Receptors, Adrenergic, beta / Q000502:physiology
chemical_list: D000318:Adrenergic beta-Agonists; D007328:Insulin; D008055:Lipids; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D004837:Epinephrine